

Reference number(s)
4258-D

**This document applies to the following:**

Formulary	Applies
Standard Control (SF)	<input type="checkbox"/>
Standard Control – Choice (SCCF)	<input type="checkbox"/>
Preferred Drug Plan Design (PDPD)	<input type="checkbox"/>
Advanced Control Specialty (ACSF)	<input type="checkbox"/>
Advanced Control Specialty – Choice (ACSCF)	<input type="checkbox"/>
Managed Medicaid Template (MMT)	<input type="checkbox"/>
Marketplace (MF)	<input type="checkbox"/>
Aetna Small Group Affordable Care Act (SG ACA)	<input type="checkbox"/>
Aetna Health Exchange (AHE)	<input type="checkbox"/>
Aetna Individual Lives (IVL)	<input type="checkbox"/>
Value (VF)	<input type="checkbox"/>

Formulary	Applies
New to Market (NTM)	<input type="checkbox"/>
Standard Formulary Chart (SFC)	<input type="checkbox"/>
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	<input type="checkbox"/>
Advanced Control Specialty Formulary Chart (ACSF)	<input type="checkbox"/>
Value Formulary Chart (VFC)	<input type="checkbox"/>
Medical Benefit	<input checked="" type="checkbox"/>
Medical Benefit: Advanced Biosimilars First	<input type="checkbox"/>
Medical Benefit: Managed Medicaid (MMMB)	<input type="checkbox"/>
Medicare Part B	<input type="checkbox"/>
Medicare Part B: Advanced Biosimilars First	<input type="checkbox"/>

# Exceptions Criteria

## Gonadotropin Releasing Hormone Agonists

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Medical Benefit.

### Plan Design Summary

This program applies to the gonadotropin releasing hormone agonist products specified in this document. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with Camcevi and Lupron Depot. This program also applies to members who are new to treatment with Firmagon, Trelstar, or Zoladex for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

## Table. Gonadotropin Releasing Hormone Agonists

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

	Product(s)
Preferred	<ul style="list-style-type: none"> <li>• Eligard (leuprolide acetate)</li> </ul>
Target	<ul style="list-style-type: none"> <li>• Camcevi (leuprolide mesylate)</li> <li>• Firmagon (degarelix)</li> <li>• Lupron Depot (leuprolide acetate for depot suspension)</li> <li>• Trelstar (triptorelin)</li> <li>• Zoladex (goserelin acetate)</li> </ul>

## Exception Criteria

This program applies to members requesting treatment for prostate cancer.

### Firmagon, Trelstar, and Zoladex

Coverage for Firmagon, Trelstar, and Zoladex is provided when any of the following criteria is met:

- Member is currently receiving treatment with the requested targeted product, excluding when the requested targeted product is obtained as samples or via manufacturer’s patient assistance programs.
- Member has a documented hypersensitivity to the preferred product.
- The request is for Firmagon and the member has metastatic, castration-naïve disease.

### Camcevi and Lupron Depot

Coverage for Camcevi and Lupron Depot is provided when the member has a documented hypersensitivity to the preferred product.

## References

1. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; May 2024.
2. Camcevi [package insert]. Durham, NC: Accord BioPharma Inc.; May 2021.
3. Firmagon [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; February 2020.
4. Lupron Depot [package insert]. North Chicago, IL: AbbVie Inc.; March 2024.
5. Trelstar [package insert]. Ewing, NJ: Verity Pharmaceuticals Inc.; April 2024.
6. Zoladex [package insert]. Deerfield, IL: TerSera Therapeutics LLC; December 2020.